证券代码：301239 证券简称：普瑞眼科 公告编号：2025-042 普瑞眼科医院集团股份有限公司 （一）审议通过《关于调整董事会成员人数并修订<公司章程>及其附件的 议案》 为进一步提高公司董事会运作和决策效率，优化公司治理，根据《公司法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第2号——创业板上市公司规范运作》等法律法规及《公司章程》的有关规 定，结合公司实际情况，公司拟修订《公司章程》及其附件，将董事会成员人 数由7人调整为5人，其中独立董事人数由3人调整为2人。 董事会提请股东会授权相关工作人员负责办理本次工商变更登记、备案手 续等具体事项，授权的有效期限自股东会审议通过之日起至本次相关工商变更 登记及章程备案办理完毕之日止。 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）披露的《关于调整 董事会成员人数并修订<公司章程>及其附件的公告》及相关公告。 表决情况：同意7票，反对0票，弃权0票。 第三届董事会第三十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情 ...

Core Insights - On October 10, 2023, Puri Eye Hospital's stock rose by 0.87%, with a trading volume of 50.26 million yuan [1] - The company reported a financing buy-in of 3.29 million yuan and a net financing buy of 135,200 yuan on the same day [1] - As of October 10, the total margin balance for Puri Eye Hospital was 70.78 million yuan, indicating a low financing balance compared to the past year [1] Financing and Margin Data - On October 10, the financing buy-in was 3.29 million yuan, while the financing repayment was 3.15 million yuan, resulting in a net buy of 135,200 yuan [1] - The current financing balance stands at 70.13 million yuan, which is 1.27% of the circulating market value, below the 10% percentile level over the past year [1] - The margin trading data shows that 200 shares were repaid, and 1,700 shares were sold short, with a short selling amount of 63,000 yuan [1] Company Overview - Puri Eye Hospital Group Co., Ltd. was established on March 23, 2006, and went public on July 5, 2022 [1] - The company provides comprehensive eye care services, including diagnosis, treatment, and optical services [1] - The revenue composition includes refractive projects (49.36%), cataract projects (19.77%), comprehensive eye disease projects (16.65%), and optical projects (13.03%) [1] Shareholder and Financial Performance - As of June 30, 2023, the number of shareholders increased by 6.24% to 10,600, while the average circulating shares per person decreased by 5.87% to 6,647 shares [2] - For the first half of 2023, Puri Eye Hospital achieved a revenue of 1.46 billion yuan, a year-on-year increase of 2.74%, but the net profit attributable to shareholders decreased by 66.12% to 14.67 million yuan [2] - Cumulatively, the company has distributed 74.51 million yuan in dividends since its A-share listing [3]

Core Viewpoint - The announcement from Puri Eye Hospital indicates that its controlling shareholder, Chengdu Puri Century Investment Co., Ltd., has pledged part of its shares, specifically 1,900,000 shares [2] Company Summary - Puri Eye Hospital's controlling shareholder has engaged in a stock pledge transaction involving 1,900,000 shares [2]

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-041 普瑞眼科医院集团股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份质押的基本情况 普瑞眼科医院集团股份有限公司（以下简称"公司"）近日接到控股股东 成都普瑞世纪投资有限责任公司（以下简称"普瑞投资"）的通知，获悉普瑞 投资将其所持有的公司部分股份办理了股票质押业务。具体事项如下： | 是否 | 为控 | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 是 | 股股 | 否 | 质 | | | | | | | | | | | | | | | | 股 | 东或 | 质 | 为 | 本次质押 | 占其所 | 占公司 | 是否 | 质押 | 押 | 东 | 第一 | 质权 | 押 | | | | | | 补 ...

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-040 普瑞眼科医院集团股份有限公司 关于独立董事任期满六年辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 普瑞眼科医院集团股份有限公司（以下简称"公司"）董事会于近日收到 公司独立董事CHEN PENGHUI先生的书面辞职报告。CHEN PENGHUI先生自2019年9 月20日起担任公司独立董事，截至2025年9月19日，连续担任公司独立董事届满 六年。根据《上市公司独立董事管理办法》相关规定，CHEN PENGHUI先生特向 公司董事会申请辞去公司第三届董事会独立董事职务，同时辞去其在董事会薪 酬与考核委员会主任委员、战略委员会委员职务。辞职后，CHEN PENGHUI先生 将不再担任公司任何职务。截至本公告披露日，CHEN PENGHUI先生未持有公司 股份，不存在应当履行而未履行的承诺事项。 二〇二五年九月二十二日 鉴于CHEN PENGHUI先生的辞职将导致公司独立董事占董事会成员的比例低 于三分之一，董事会相关专门委员会中独立董事人数未达要求，为保证公司董 事会的规范运作 ...

国泰海通证券股份有限公司 关于普瑞眼科医院集团股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐人名称：国泰海通证券股份有限公司 | 被保荐公司简称：普瑞眼科 | | --- | --- | | 保荐代表人姓名：田卓玲 | 联系电话：13520345327 | | 保荐代表人姓名：李沁杭 | 联系电话：18526793477 | | 报告事项 | 说明 | | --- | --- | | | 是，2025 年 4 月 8 日，原保荐代表人朱玉峰 | | | 先生因工作安排原因，无法继续从事对公司 | | | 的持续督导工作。为保证持续督导工作的有 | | 1.保荐代表人变更及其理由 | 序进行，国泰海通现委派保荐代表人李沁杭 | | | 先生接替朱玉峰先生继续履行持续督导工 | | | 作。 | | | 原国泰君安证券股份有限公司（以下简称"国 | | | 泰君安"）换股吸收合并原海通证券股份有限 | | | 公司（以下简称"海通证券"）事项已获得中 | | | 国证券监督管理委员会核准批复，本次合并 | | | 交易已于 2025 年 3 月 14 日（即"交割日"） | | | 完成交割，自该日起 ...

Core Viewpoint - The company anticipates challenges in revenue growth across its business segments in Q2 2025 due to a slowdown in overall demand and intensified industry competition, particularly affecting its cataract project revenue [1] Group 1: Revenue and Performance - The company's revenue is expected to decline in Q2 2025, influenced by the centralized procurement policy for artificial lenses and reforms in medical insurance payment methods [1] - Despite the anticipated decline in Q2, the company expects stable overall revenue and operating cash flow in the first half of 2025 [1] Group 2: Industry Trends and Technological Advancements - Continuous advancements in ophthalmic medical technology, such as femtosecond-assisted cataract surgery and new techniques like all-laser 4.0 and all-laser pro, are expected to enhance treatment outcomes for patients [1] - These technological improvements may help optimize the company's business structure and elevate performance levels [1] Group 3: Management Outlook - The management expresses confidence in the company's long-term development despite the short-term challenges [1]

Core Viewpoint - The ophthalmology medical industry is experiencing a slowdown in the growth of refractive surgery revenue, with many companies reporting single-digit growth rates in this segment, while a few are still achieving double-digit growth. Group 1: Industry Overview - The refractive surgery business, a significant revenue source for private ophthalmology institutions, has shown a general trend of slowing growth in recent years [1] - Among five listed ophthalmology companies in A-shares, three reported refractive project revenue growth at single-digit levels or below in the first half of the year [1] - Specific growth figures include: - Puyi Eye Hospital (301239.SZ) with a 4.13% increase to 720 million yuan, accounting for 49% of total revenue [1] - He’s Eye Hospital (301103.SZ) with a 3.26% increase to 135 million yuan, accounting for 24% of total revenue [1] - Guangzheng Eye Hospital (002524.SZ) with a 0.32% increase to 142 million yuan, accounting for 32.71% of total revenue [1] - Aier Eye Hospital (300015.SZ) and Huaxia Eye Hospital (301267.SZ) are exceptions, achieving revenue growth rates of 11.4% and 13.75%, respectively [1] Group 2: Company Strategies - Aier Eye Hospital attributes its revenue growth in refractive projects to the acceptance of new surgical techniques such as All-Laser LASIK and the expansion of its medical network, enhancing patient coverage [3] - Puyi Eye Hospital is focusing on introducing authoritative expert teams and updating high-end diagnostic equipment to cultivate new growth points in the competitive refractive and vision care market [3] Group 3: Market Demand and Trends - The current refractive surgery patient population is divided into two categories: those with essential needs due to academic or professional requirements and those seeking aesthetic improvements [4] - Despite a stable demand from the essential needs group, the decision-making cycle for non-essential consumers is lengthening due to macroeconomic factors [4] - There is significant unmet demand in the refractive surgery market, with approximately 700 million myopic patients in China, but only about 1 million undergoing surgery annually [4] - The Z generation shows a personalized and urgent demand for vision correction, driving innovation and iteration in refractive surgery technologies [4] - Aierkon has introduced new refractive surgery solutions, such as All-Laser LASIK, which allows for personalized treatment based on various eye data [4] Group 4: Technology Adoption - Aierkon's All-Laser LASIK equipment has seen over 50,000 surgeries performed since its launch at the 2023 China International Import Expo, with over 100 hospitals equipped nationwide [5] - The company emphasizes the need for continued market education to enhance the penetration of new technologies [5]

Core Viewpoint - The refractive surgery business of private ophthalmology medical institutions is experiencing a slowdown in revenue growth, with several companies reporting single-digit growth rates in their refractive project revenues [1][2]. Group 1: Revenue Growth Analysis - Among five listed ophthalmology medical companies, three reported refractive project revenue growth at single-digit levels or below in the first half of the year. Specifically, Purui Eye Hospital (301239.SZ) saw a 4.13% increase to 720 million yuan, accounting for 49% of its total revenue; He’s Eye Hospital (301103.SZ) reported a 3.26% increase to 135 million yuan, making up 24% of its revenue; and Guangzheng Eye Hospital (002524.SZ) had a 0.32% increase to 142 million yuan, representing 32.71% of its revenue [1]. - In contrast, Aier Eye Hospital (300015.SZ) and Huaxia Eye Hospital (301267.SZ) managed to maintain double-digit growth rates in their refractive project revenues, with increases of 11.4% and 13.75%, respectively [1]. Group 2: Competitive Strategies - To navigate the competitive refractive surgery market, companies are leveraging new technologies. Aier Eye Hospital reported that its revenue growth in refractive projects is driven by the acceptance of new surgical techniques such as all-laser and full-femtosecond procedures, which have improved the business structure and increased average prices [2]. - Purui Eye Hospital is also responding to market competition by continuously introducing authoritative expert teams and updating high-end diagnostic equipment to cultivate new growth points [2]. Group 3: Market Demand and Trends - The current refractive surgery patient population can be divided into two groups: one with essential needs due to academic or professional requirements, and another seeking aesthetic improvements by eliminating glasses or contact lenses [2]. - Despite the large number of myopic patients in China, estimated at around 700 million, only about 1 million undergo refractive surgery annually, indicating significant unmet demand and potential for market penetration [3]. - The Z generation shows a personalized and urgent demand for vision correction, pushing for technological innovation and customization in refractive surgery [3].